2. Signaling Pathways
  3. Immunology/Inflammation
  4. CD73

CD73

ecto-5′-nucleotidase, NT5E

CD73

Related Products

PDF 0.28 MB

CD73 (Ecto-5′-nucleotidase) is a 70-kD glycosylphosphatidyl inositol (GPI)-anchored cell surface protein encoded by the NT5E gene that plays a crucial role in switching on adenosinergic signaling. CD73 is an ectonucleotidase which catalyzes the terminal step in extracellular adenine nucleotide breakdown: the conversion of AMP to adenosine. Adenosine, which binds to a discrete family of cell surface receptors to initiate intracellular signaling cascades, has been shown to be anti-inflammatory and vasorelaxant.

CD73 has both enzymatic and non-enzymatic functions in cells: as a nucleotidase, CD73 catalyzes the hydrolysis of AMP into adenosine and phosphate, and CD73-generated adenosine plays an important role in tumor immunoescape; moreover, CD73 also functions as a signal and adhesive molecule that can regulate cell interaction with extracellular matrix components, such as laminin and fibronectin, to mediate the invasive and metastatic properties of cancers. Both the enzymatic and non-enzymatic functions of CD73 are involved in cancer-associated processes and are not completely independent of each other. There is ample evidence to show that CD73 is a key regulatory molecule in cancer development and is overexpressed in many cancers, including leukemia, glioblastoma, melanoma, ovarian cancer, esophageal cancer, prostate cancer and breast cancer.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-147592
    CD73-IN-11
    		Inhibitor
    CD73-IN-11 is a potent inhibitor of CD73. CD73 can catalyze the production of adenosine from extracellular 5'-phosphate adenosine (5'-AMP), and adenosine can induce immunosuppressive effects and promote tumor proliferation and/or metastasis. CD73-IN-11 be used for preparing a medicament for tumor-related diseases (extracted from patent WO2022068929A1, compound 24).
    CD73-IN-11
  • HY-131435
    CD73-IN-2
    		Inhibitor
    CD73-IN-2 is a potent CD73 inhibitor extracted from WO2020151707A1, example 1, has an IC50 of 0.09 nM.
    CD73-IN-2
  • HY-147591
    CD73-IN-10
    		Inhibitor
    CD73-IN-10 is a potent inhibitor of CD73. CD73 can catalyze the production of adenosine from extracellular 5'-phosphate adenosine (5'-AMP), and adenosine can induce immunosuppressive effects and promote tumor proliferation and/or metastasis. CD73-IN-10 be used for preparing a medicament for tumor-related diseases (extracted from patent WO2022068929A1, compound 4).
    CD73-IN-10
  • HY-147594
    CD73-IN-13
    		Inhibitor
    CD73-IN-13 is a potent inhibitor of CD73. CD73 is closely associated with tumor growth, angiogenesis and metastasis. CD73-IN-13 be used for preparing a medicament for tumor-related diseases (extracted from patent CN114437039A, compound 7).
    CD73-IN-13
  • HY-147589
    CD73-IN-8
    		Inhibitor
    CD73-IN-8 is a potent inhibitor of CD73. CD73 can catalyze the production of adenosine from extracellular 5'-phosphate adenosine (5'-AMP), and adenosine can induce immunosuppressive effects and promote tumor proliferation and/or metastasis. CD73-IN-8 be used for preparing a medicament for tumor-related diseases (extracted from patent WO2022052886A1, compound 57).
    CD73-IN-8
  • HY-152074
    CD73-IN-14
    		Inhibitor
    D73-IN-14 is a potent, selective and orally active CD73 inhibitor with an IC50 value of 0.17 nM. CD73-IN-14 increases the number of tumor-infiltrating CD8+ cells and shows anti-tumor activity. CD73-IN-14 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    CD73-IN-14
  • HY-144072
    MRS4620
    		Inhibitor
    MRS4620 is a potent CD73 inhibitor, with a Ki of 0.436 nM. MRS4620 can be use for the research of cancer immunoresearch.
    MRS4620
  • HY-147590
    CD73-IN-9
    		Inhibitor
    CD73-IN-9 is a potent inhibitor of CD73. CD73 can catalyze the production of adenosine from extracellular 5'-phosphate adenosine (5'-AMP), and adenosine can induce immunosuppressive effects and promote tumor proliferation and/or metastasis. CD73-IN-9 be used for preparing a medicament for tumor-related diseases (extracted from patent WO2022068929A1, compound 2).
    CD73-IN-9
  • HY-100747A
    PSB-12379 disodium
    		Inhibitor
    PSB-12379 disodium, a nucleotide analogue, is a potent Ecto-5'-Nucleotidase (CD73) inhibitor with Kis of 9.03 nM (rat) and 2.21 nM (human).
    PSB-12379 disodium
  • HY-162917
    CD73-IN-16
    		Inhibitor
    CD73-IN-16 (compound 18) is an inhibitor of hCD73 with IC50 values of 0.28 μM.
    CD73-IN-16
  • HY-146759
    ZM514
    		Inhibitor
    ZM514 is a potent CD73 inhibitor with IC50s of 1.39 μM and 14.65 μM for hCD73 and mCD73, respectively. ZM514 has low cytotoxicity. ZM514 can be used for researching anticancer.
    ZM514
  • HY-162554
    CD73-IN-15
    		Inhibitor
    CD73-IN-15 (compound 12f) is a potent inhibitor of CD73, with the IC50 of 60 nM. CD73-IN-15 plays an important role in cancer research.
    CD73-IN-15
  • HY-147593
    CD73-IN-12
    		Inhibitor
    CD73-IN-12 is a potent inhibitor of CD73. CD73 is closely associated with tumor growth, angiogenesis and metastasis. CD73-IN-12 be used for preparing a medicament for tumor-related diseases (extracted from patent CN114437038A, compound 9). CD73-IN-12 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    CD73-IN-12
  • HY-169189
    CD73-IN-18
    		Inhibitor
    CD73-IN-18 (compound 35j) is an orally available inhibitor of extracellular 5-nucleotidase (CD73). CD73-IN-18 can be used in anti-cancer research.
    CD73-IN-18
  • HY-P99841
    Dalutrafusp alfa
    		Inhibitor
    Dalutrafusp alfa (AGEN-1423; GS-1423) is a specific bifunctional antibody against CD73 and TGF-β, which is involved in the immunosuppressive pathway.
    Dalutrafusp alfa
  • HY-150048
    BK50164
    		Inhibitor
    BK50164 is a potent CD73 inhibitor with an IC50 value of 13.089 µM. BK50164 binds to CD99 with a KD value of 1.5 µM. BK50164 shows antiproliferative activity. BK50164 induced Apoptosis.html" class="link-product" target="_blank">Apoptosis and cell cycle arrest at Sub-G1 phase.
    BK50164
  • HY-144209
    CD73-IN-6
    		Inhibitor
    CD73-IN-6 is a CD73 inhibitor extracted from patent WO2022007677A1 compound 2. CD73-IN-6 can be used for the research of cancer.
    CD73-IN-6
  • HY-147588
    CD73-IN-7
    		Inhibitor
    CD73-IN-7 is a potent inhibitor of CD73. CD73 can catalyze the production of adenosine from extracellular 5'-phosphate adenosine (5'-AMP), and adenosine can induce immunosuppressive effects and promote tumor proliferation and/or metastasis. CD73-IN-7 be used for preparing a medicament for tumor-related diseases (extracted from patent WO2022052886A1, compound 13).
    CD73-IN-7
  • HY-161677
    PD-L1/CD-73-IN-1
    		Inhibitor
    PD-L1/CD-73-IN-1 (compound CC-5) is PD-L1/CD73 inhibitor with IC50 values of 6 nM and 0.773 μM to PD-L1 and CD73, respectively. PD-L1/CD-73-IN-1 inhibits tumor cell growth in vivo and in vitro.
    PD-L1/CD-73-IN-1
  • HY-112502A
    MethADP disodium
    		Inhibitor
    MethADP disodium is a specific CD73 inhibitor.
    MethADP disodium
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity